Journal Title：Nuclear Medicine And Biology

Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized.

These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field.

Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.

Nuclear Medicine and Biology 发表涉及放射性药物科学各个方面的原创研究：合成、体外和离体研究、通过解剖或成像进行的体内生物分布、放射性药理学、放射性药物学以及新靶向放射性示踪剂的转化临床研究。应首先考虑目标对未满足临床需求的重要性。如果提交的新放射性药物合成没有体外或体内数据，则必须强调化学的独特性。

这些多学科研究应验证定位机制，无论探针是基于与受体、酶、肿瘤抗原还是其他明确目标的结合。研究应旨在评估化学和放射性药物特性如何影响药代动力学、药效学或治疗效果。理想情况下，该研究将解决探针对疾病或治疗变化的敏感性，尽管单独验证机制的研究是可以接受的。放射性药物实践，解决制备、自动化、质量控制、分配和适用于人类放射性药物鉴定和管理的法规问题，是发展过程的一个重要方面，但前提是该研究对该领域有重大影响。

只要已解决标记化合物定位的特异性和治疗效果，对治疗性放射性药物主题的贡献也是适当的。